Ranked #1,253 of 8,699 institutional investors
Soleus Capital Management, L.P.
Greenwich, CT
$2.64B
US stock portfolio at live prices · today −$22.6M (−0.85%)
Live prices, last trade 11:50 AM ET
- Value at quarter end (Q3 2026)
- $2.81B
- Change from Q2 2026
- −$89.0M (−3.07%)
- Positions
- 88 · 24 new, 25 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$228M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesKRYS 13.5%PODD 9.01%TGTX 6.24%UTHR 5.45%CELC 3.46%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| KRYS Krystal Biotech, Inc. | 1,139,700 | $356M | 13.5% | Added +21% |
| PODD Insulet Corporation | 1,726,500 | $238M | 9.01% | Added +65% |
| TGTX TG Therapeutics, Inc. | 2,556,168 | $165M | 6.24% | Reduced −13% |
| UTHR United Therapeutics Corporation | 259,000 | $144M | 5.45% | Added +15% |
| CELC Celcuity Inc. | 1,682,760 | $91.3M | 3.46% | Reduced −1% |
| VCEL Vericel Corporation | 1,554,059 | $90.5M | 3.42% | Added +7% |
| RIGL Rigel Pharmaceuticals, Inc. | 1,843,504 | $74.2M | 2.81% | Unchanged |
| ERAS Erasca, Inc. | 5,112,000 | $71.8M | 2.72% | Added +89% |
| INSP Inspire Medical Systems, Inc. | 1,206,828 | $67.0M | 2.54% | Reduced −38% |
| ANIP ANI Pharmaceuticals, Inc. | 975,500 | $66.9M | 2.53% | Added +12% |
| AXGN Axogen, Inc. | 1,081,000 | $60.3M | 2.28% | Added +1,795% |
| PGNY Progyny, Inc. | 1,582,000 | $56.7M | 2.15% | Reduced −1% |
| BBNX Beta Bionics, Inc. | 3,743,714 | $50.6M | 1.92% | Reduced −15% |
| SLN Silence Therapeutics plc | 2,385,700 | $47.2M | 1.79% | Added +279% |
| PBLS Parabilis Medicines, Inc. | 1,684,512 | $46.8M | 1.77% | Added +15% |
| ARGX argenx SE | 49,350 | $46.4M | 1.75% | Added +147% |
| GERN Geron Corporation | 46,768,659 | $42.4M | 1.61% | Added +9% |
| TRVI Trevi Therapeutics, Inc. | 2,727,727 | $36.8M | 1.39% | Added +131% |
| EOLS Evolus, Inc. | 5,090,000 | $35.4M | 1.34% | Added +519% |
| NVCT Nuvectis Pharma, Inc. | 1,710,658 | $33.1M | 1.25% | Added +71% |
| ZLAB Zai Lab Limited | 1,543,000 | $31.9M | 1.21% | New |
| AVLN Avalyn Pharma Inc. | 1,019,000 | $28.7M | 1.09% | Added +143% |
| KOD Kodiak Sciences Inc. | 286,966 | $28.2M | 1.07% | New |
| NPCE NeuroPace, Inc. | 3,218,000 | $25.4M | 0.96% | Added +11% |
| KIDS OrthoPediatrics Corp. | 710,198 | $22.8M | 0.86% | Reduced −3% |
| INSM Insmed Incorporated | 147,000 | $21.3M | 0.81% | Added +63% |
| FOCL EDAP TMS S.A. | 7,309,254 | $20.4M | 0.77% | Unchanged |
| ETON Eton Pharmaceuticals, Inc. | 308,101 | $18.4M | 0.70% | New |
| JBIO Jade Biosciences, Inc. | 1,170,928 | $17.9M | 0.68% | Reduced −24% |
| TNGX Tango Therapeutics, Inc. | 802,297 | $17.8M | 0.67% | Added +13% |
| PRAX Praxis Precision Medicines, Inc. | 56,515 | $17.3M | 0.66% | Reduced −68% |
| LEGN Legend Biotech Corporation | 1,085,550 | $17.0M | 0.64% | Reduced −10% |
| CNMD CONMED Corporation | 347,333 | $16.1M | 0.61% | New |
| PRCT PROCEPT BioRobotics Corporation | 600,358 | $15.4M | 0.58% | Reduced −40% |
| INBX Inhibrx Biosciences, Inc. | 210,000 | $15.0M | 0.57% | New |
| IKT Inhibikase Therapeutics, Inc. | 11,225,000 | $14.6M | 0.55% | Added +3% |
| AMRX Amneal Pharmaceuticals, Inc. | 658,000 | $13.9M | 0.53% | New |
| PALI Palisade Bio, Inc. | 14,996,154 | $13.7M | 0.52% | Added +15% |
| RCUS Arcus Biosciences, Inc. | 862,000 | $13.7M | 0.52% | Reduced −26% |
| EWTX Edgewise Therapeutics, Inc. | 329,987 | $13.3M | 0.51% | Reduced −27% |
| MBX MBX Biosciences, Inc. | 258,897 | $13.3M | 0.50% | Reduced −50% |
| SEPN Septerna, Inc. | 330,000 | $12.9M | 0.49% | Added +20% |
| SNY Sanofi | 275,000 | $12.8M | 0.48% | New |
| NRIX Nurix Therapeutics, Inc. | 892,163 | $11.7M | 0.44% | Reduced −39% |
| ANL Adlai Nortye Group Ltd. | 1,272,355 | $11.2M | 0.42% | Added +214% |
| GRAL GRAIL, Inc. | 108,500 | $10.8M | 0.41% | New |
| PRLD Prelude Therapeutics Incorporated | 3,378,378 | $10.8M | 0.41% | Unchanged |
| ORGO Organogenesis Holdings Inc. | 11,300,951 | $9.0M | 0.34% | Added +11% |
| TYRA Tyra Biosciences, Inc. | 445,025 | $8.9M | 0.34% | New |
| CCCC C4 Therapeutics, Inc. | 3,357,981 | $8.3M | 0.32% | Reduced −1% |
| LUNG Pulmonx Corporation | 3,088,323 | $8.2M | 0.31% | Added +11% |
| XENE Xenon Pharmaceuticals Inc. | 205,000 | $7.7M | 0.29% | Reduced −23% |
| BMRN BioMarin Pharmaceutical Inc. | 121,120 | $7.4M | 0.28% | Reduced −68% |
| GKOS Glaukos Corporation | 25,552 | $6.1M | 0.23% | New |
| TRAX First Tracks Biotherapeutics, Inc. | 140,500 | $5.9M | 0.22% | New |
| RVMD Revolution Medicines, Inc. | 36,249 | $5.9M | 0.22% | New |
| YARW Yarrow Bioscience, Inc. | 416,993 | $5.8M | 0.22% | New |
| CAPR Capricor Therapeutics, Inc. | 699,149 | $5.6M | 0.21% | Reduced −8% |
| SNDX Syndax Pharmaceuticals, Inc. | 615,990 | $5.5M | 0.21% | Reduced −62% |
| BDSX Biodesix, Inc. | 667,835 | $5.3M | 0.20% | Added +14% |
| TWST Twist Bioscience Corporation | 47,532 | $5.0M | 0.19% | Reduced −55% |
| CSTL Castle Biosciences, Inc. | 141,137 | $4.6M | 0.18% | New |
| IOVA Iovance Biotherapeutics, Inc. | 551,977 | $3.9M | 0.15% | Added +268% |
| IVVD Invivyd, Inc. | 7,524,958 | $3.4M | 0.13% | Reduced −2% |
| AVTX Avalo Therapeutics, Inc. | 383,594 | $2.6M | <0.1% | Reduced −77% |
| SLDB Solid Biosciences Inc. | 368,123 | $2.3M | <0.1% | Added +145% |
| ETRA Electra Therapeutics, Inc. | 250,000 | $2.1M | <0.1% | New |
| MSLE Satellos Bioscience Inc. | 330,102 | $1.9M | <0.1% | Added +5% |
| SABS SAB Biotherapeutics, Inc. | 672,039 | $1.8M | <0.1% | Reduced −25% |
| TNDM Tandem Diabetes Care, Inc. | 100,000 | $1.8M | <0.1% | Reduced −83% |
| WAY Waystar Holding Corp. | 50,000 | $1.3M | <0.1% | New |
| CNTX Context Therapeutics Inc. | 7,063,141 | $1.2M | <0.1% | Unchanged |
| MNKD MannKind Corporation | 300,100 | $1.2M | <0.1% | New |
| ZNTL Zentalis Pharmaceuticals, Inc. | 706,280 | $982K | <0.1% | Reduced −26% |
| CERS Cerus Corporation | 450,000 | $853K | <0.1% | Reduced −82% |
| NXTC NextCure, Inc. | 90,000 | $599K | <0.1% | New |
| NSPR InspireMD, Inc. | 1,045,708 | $594K | <0.1% | Unchanged |
| SUPN Supernus, Inc. | 10,000 | $291K | <0.1% | Reduced −99% |
| APRE Aprea Therapeutics, Inc. | 1,000,000 | $270K | <0.1% | New |
| PCSA Processa Pharmaceuticals, Inc. | 160,943 | $243K | <0.1% | New |
| UNH UnitedHealth Group Incorporated | 660 | $228K | <0.1% | Reduced −99% |
| BNTX BioNTech SE | 2,500 | $202K | <0.1% | New |
| BLTE Belite Bio, Inc | 1,524 | $199K | <0.1% | Reduced −97% |
| VIR Vir Biotechnology, Inc. | 20,971 | $181K | <0.1% | Reduced −98% |
| QDEL QuidelOrtho Corporation | 20,000 | $170K | <0.1% | New |
| ATTO Attovia Therapeutics, Inc. | 10,000 | $151K | <0.1% | New |
| EQ Equillium, Inc. | 90,000 | $103K | <0.1% | Unchanged |
| RXST RxSight, Inc. | 20,000 | $91K | <0.1% | New |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| GMED Globus Medical, Inc. | 468,922 | $31.7M |
| SYRE Spyre Therapeutics, Inc. | 147,000 | $14.0M |
| IMVT Immunovant, Inc. | 252,000 | $8.1M |
| ELVN Enliven Therapeutics, Inc. | 165,677 | $7.7M |
| MIRM Mirum Pharmaceuticals, Inc. | 75,000 | $7.3M |
| AORT Artivion, Inc. | 388,000 | $7.2M |
| MRK Merck & Co., Inc. | 50,000 | $6.8M |
| ALNY Alnylam Pharmaceuticals, Inc. | 33,050 | $5.0M |
| NKTR Nektar Therapeutics | 128,362 | $4.0M |
| IMUX Immunic, Inc. | 450,000 | $3.2M |
| RLMD Relmada Therapeutics, Inc. | 842,106 | $2.4M |
| TECX Tectonic Therapeutic, Inc. | 101,684 | $2.1M |
| GPCR Structure Therapeutics Inc. | 107,000 | $1.8M |
| CORT Corcept Therapeutics Incorporated | 19,653 | $1.3M |
| VCYT Veracyte, Inc. | 25,000 | $623K |
| LRMR Larimar Therapeutics, Inc. | 188,102 | $567K |
| AVBP ArriVent BioPharma, Inc. | 50,000 | $549K |
| SION Sionna Therapeutics, Inc. | 177,687 | $510K |
| WGS GeneDx Holdings Corp. | 10,000 | $471K |
| CGEM Cullinan Therapeutics, Inc. | 50,000 | $450K |
| CGON CG Oncology, Inc. | 5,000 | $409K |
| NTRA Natera, Inc. | 1,000 | $277K |
| QNRX Quoin Pharmaceuticals, Ltd. | 72,730 | $253K |
| NEO NeoGenomics, Inc. | 10,000 | $149K |
| KPTIQ Karyopharm Therapeutics Inc. | 440,000 | $15K |